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Background: Though financial and policy level efforts are made to expand antiretroviral treatment (ART) service
free of cost, survival outcome of ART program has not been systematically evaluated in Nepal. This study assesses
the mortality rates and determinants among adult HIV-infected patients on ART in Far-western region of Nepal.
Methods: This retrospective cohort study included 1024 (51.2% men) HIV-infected patients aged ≥15 years, who
started ART between May 15th 2006 and May 15th 2011 in five ART sites in the Far-western region, Nepal. Follow-up
time was calculated from the date of ART initiation to date of death or censoring (loss to follow-up, transferred out,
or 15 November 2011). Mortality rates (per 100 person-years) were calculated. Kaplan-Meier and Cox-regression
models were used to estimate survival and explore determinants of mortality.
Results: The median follow-up time was 19.1 months. The crude mortality rate was 6.3 (95% confidence interval
(CI) 5.3-7.6) but more than three-times higher in first 3 months after ART initiation (21.9 (95% CI 16.6- 28.8)). About
12% (83% men) of those newly initiated on ART died during follow-up. The independent determinants of mortality
were male sex (hazard ratio (HR) 4.55, 95% CI 2.43-8.51), poor baseline performance scale (bedridden <50% of the
day during the past month, HR 2.05, 95% CI 1.19-3.52; bedridden >50% of the day during the past month, HR 3.41,
95% CI 1.67-6.98 compared to normal activity), one standard deviation decrease in baseline bodyweight (HR 1.04,
95% CI 1.01-1.07), and poor WHO clinical stage (stage III, HR 2.96, 95% CI 1.31-6.69; stage IV, HR 3.28, 95% CI 1.30-8.29
compared to WHO clinical stage I or II).
Conclusions: High mortality was observed within the first 3 months of ART initiation. Patients with poor baseline
clinical characteristics had higher mortality, especially men. Earlier initiation of ART through expanded testing and
counselling should be encouraged in HIV-infected patients.
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It has been estimated that antiretroviral treatment (ART)
has averted 300,000 HIV-related deaths in Asia [1]. Al-
though it is well established that ART reduces mortality
and prevent opportunistic infection among HIV patients
in high-income countries and in generalized epidemics in
Africa, mortality rates and mortality determinants among
ART-recipients in countries with concentrated epidemics* Correspondence: lax_b1@yahoo.com
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reproduction in any medium, provided the orin the South Asian region have not been well-covered
[2-6]. There is reason to believe that there are large re-
gional variations in terms of treatment outcomes due to
poor access to services in particular among most at risk of
HIV-infection and minority populations with stigmatized
risk behaviours [4,7,8].
Nepal is among the poorest countries in the world and
health programs, especially HIV programs are heavily
donor dependent [7]. Nepal has a concentrated HIV epi-
demic with a low estimated HIV prevalence of 0.30%
among adults (15–49 years) in the general population
but over 5-fold higher rates among populations at higherLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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where they often visit sex workers), men who have sex
with men, female sex workers, people who inject drugs
[7,9]. These population groups are considered important
bridging populations for HIV transmission between
high-risk and low-risk shares of the populations [7,10].
Since the introduction of free ART services in Nepal in
2004 with a primary aim to reduce mortality among HIV-
infected patients, there have been improvements in service
delivery and utilization. In addition to the free-of-cost
highly affective antiretroviral therapy, HIV-infected pa-
tients are offered care package including clinical follow-
up monitoring, TB screening and Isoniazid preventive
therapy, and community and home-based care (CHBC),
which includes primary care of patients by trained
CHBC workers at homes and community settings aim-
ing for positive living, reducing stigma and discrimin-
ation if any, and supporting for sanitation and hygiene,
continuity and adherence to ART. Moreover, medical,
nutritional, psychosocial, legal support is provided by
CHBC, and in addition financial support is provided
to newly enrolled patients by community care centers
nearby ART sites [11,12]. However, the ART coverage of
people eligible to treatment is still low despite a doub-
ling from 10% in 2007 to 24% of those in need (having a
CD4 count <350 cells/mm3) in 2011 [9,13]. No previous
systematic review has been done in Nepal, but it is
needed to better understand the most important deter-
minants of mortality among patients initiated on ART
in order to identify those at the highest risk of prevent-
able death. This cohort study explores the mortality
rates and determinants among all known ART patients
in one of the five development regions of Nepal, the
Far-western region, in a thorough retrospective assess-
ment including the most recent available data since the
start of ART in this area, i.e. from 2006 to 2011.
Methods
Study setting
The Far-western region (population 2.5 million [14]) is a
remote and developmentally challenged region of Nepal
[15]. There are seven ART sites in the Far-western re-
gion of Nepal. All the ART sites in the region are run by
government hospitals except Bayalpata hospital in Achham
district that is run by a non-governmental organization.
Five ART sites (Seti Zonal Hospital and Tikapur Hospital,
Kailali district; Mahakali Zonal Hospital, Kanchanpur
district; Achham District Hospital, Achham district;
Doti District Hospital, Doti district) in the region have
treatment initiation capabilities, while two ART sites
(Baitadi District Hospital, Baitadi district; Bayalpata
Hospital, Achham district) only offer treatment follow-
up for transferred-in HIV-positive patients who were
tested and started the treatment at other ART siteswithin or outside the region. Patients were transferred
to these two sites in order to ease their access to treat-
ment near their place of residence. These two sites were
ineligible for this study due to lack or incomplete base-
line information and ART initiation date.
Study population
The study population consisted of all adult HIV-infected
patients (15 years of age and older) on ART, who started
the treatment between May 15th 2006 (first recipient re-
corded in ART site of Far-western region) and May 15th
2011 at any of the five eligible ART sites in the Far-western
region. All patients with history of previous treatment, and
children aged 0–14 years -as defined by the National
Centre for AIDS and STD control (NCASC), Ministry of
Health and Population (MoHP), Nepal [9] were excluded
from the study. The total eligible population was 1286
adult HIV-infected patients and they were followed-up
with respect to death until 15 November 2011 (Figure 1).
Data collection and study variables
Data were collected from standard medical record regis-
ters at ART sites adopted by the NCASC, Nepal. There
were three available registers. The first register was the
Pre-ART register where all confirmed HIV-positive cli-
ents who visit ART site were registered. Then, all the pa-
tients who started ART regimen were transferred to an
ART register at the date of treatment initiation. The
third register was patient’s follow-up form. For every pa-
tient, the first follow-up visit was scheduled two weeks
after treatment initiation and then on a monthly basis,
where medical records were updated for every patient
during each follow-up visit. Data collection approval was
obtained from all ART sites. Confidentiality and ano-
nymity of data was maintained during data collection.
Ethical approval was obtained from the Nepal Health
Research Council (NHRC), Kathmandu, Nepal.
Patients’ baseline demographic and clinical character-
istics data were collected. Baseline demographic charac-
teristics included place of ART site, age (in years), sex,
and education. Clinical characteristics at the time of
ART initiation included performance scale, bodyweight
(kg), World Health Organization (WHO) clinical stage,
CD4 count (cells/mm3), ART regimen, drug toxicity/side
effects, and active tuberculosis (TB) during treatment.
Performance scale was categorized and recorded into
three groups: normal activity, bedridden <50% of the day
during the past month, bedridden >50% of the day dur-
ing the past month [16]. The clinical stage of the HIV-
infected patient was assessed and recorded using the
WHO clinical stage guidelines [16] based on load of
clinical symptoms and infections reported by the health
professionals at ART sites. The WHO clinical stage was
categorized into four groups (stage I, stage II, stage III,
Figure 1 Profile of the study cohort.
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health condition [16]. The first line ART regimens in
adults and adolescent are ZDV/3TC/NVP, ZDV/3TC/
EFV, d4T/3TC/NVP, d4T/3TC/EFV, TDF/3TC/NVP, and
TDF/3TC/EFV. In case of treatment failure, it is recom-
mended to change to second line combination regimen.
The second line regimens in adults and adolescent are
TDF + 3TC + LVP/r and ZDF + 3TC + LVP/r [16].
The date of death was recorded for all HIV-infected
patients, who died from all causes during the study
period while on antiretroviral treatment. Patients miss-
ing their follow-up visits for more than 3 months were
counted as loss to follow-up and the date of the last reg-
istered follow-up visit was recorded as date of loss to
follow-up. ART using HIV-infected patient, who were
transferred to another ART site, were recorded as
transferred-out cases and their dates of transferred-out
were also recorded.
Data analysis
Adult HIV-infected patients who had no follow-up visits
(n = 25) and, patients without date of ART initiation and
date of occurrence of events (i.e. death, loss to follow
up, and transferred out) (n = 196) were excluded from
study. An additional 41 patients were excluded due to
invalid follow-up information on at least one follow-up
visit (for example, transferred out date earlier than first
follow-up visit date). A total of 1024 adult HIV-infected
patients were included in the present analysis (Figure 1).
Follow-up time (in months) was calculated from the
date of ART initiation to the date of death or censoring
(loss to follow-up, transferred out, or 15 November
2011). Kaplan-Meier (KM) models were used to estimate
survival probability after ART initiation. All the baselinedemographic and clinical characteristics were used as in-
dependent variables in the analysis. Proportional hazard
assumption was assessed and all the independent vari-
ables satisfied the assumption. The Cox-proportional
hazard model was used to assess the relationship be-
tween the independent variables and mortality. The uni-
variate Cox-regression analysis was used to estimate the
unadjusted Hazard Ratios (HRs), and the stepwise (back-
ward LR) multivariate Cox-regression analysis (including
all independent variables) was performed to estimate the
adjusted hazard ratios. The probability for the stepwise
regression was 0.05 for entry of the variables and 0.10
for removal of the variables from model. All the tests
were two-sided and the criterion for statistical signifi-
cance was set at p < 0.05. A worst-case-scenario analysis
was performed assuming all lost to follow-up patients
were dead immediately after the last date of contact.
Data were analysed using the statistical software STATA
version 12.0 and SPSS version 16.0.
Results
Among the 1024 adult HIV-infected patients, 14 (1.4%)
were lost to follow-up, 198 (19.3%) were transferred-out
to other ART site within Far-western region or outside
the region, 120 (11.7%) died, and 692 (67.6%) were still
alive by the 15 November 2011. Among 120 patients
who died, 51 (42.5%) died within 3 months after start of
treatment. There was inadequate information regarding
the causes of deaths among adult HIV-infected patients
on ART.
The overall median follow-up time of all the patients
was 19.1 months or 1.6 years (Interquartile range 0.6 –
2.9 years). The median follow-up time of the deceased
(3.6 months) and lost to follow-up patients (13.2 months)
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(29.5 months). The overall survival probability among
adult HIV-infected patients declined over follow-up
time (Figure 2). The survival probability of patients at
3 month, 6 month, 1 year, 2 year, and at 5 year was 94.7%,
91.4%, 89.7%, 86.5% and 82.9% respectively.
The study cohort contributed a total of 1895 person-
years of follow-up. The total mortality rate was 6.3 per
100 person-years at risk. The mortality rate was highest
in the first three months after ART initiation (21.9 per
100 person-years (95% CI 16.6-28.8)) (Table 1).
The baseline demographic and clinical characteristics
of adult HIV-infected patients on ART are summarized
in Table 2. The median age of the patients at start of
ART was 35 years (Interquartile range 30–42 years), and
male patients constitute 51.2% of the total sample size.
About 1 out of 11 patients were bedridden for >50% of
the day during the past month. The median baseline
bodyweight was 45 kg (Interquartile range 40–50). The
median baseline CD4 count was 149 cells/mm3 (Inter-
quartile range was 80–210). About 17% of patients were
in WHO clinical stage IV, where one out of four died.
The proportions of deaths varied between the ART sites
(p-value for χ2 test was 0.001).
Table 3 shows the hazard ratios from the univariate and
multivariate analysis of the association between the pos-
sible determinants of mortality and risk of death. In uni-
variate analysis, place of ART site, sex, age, baseline
performance scale, bodyweight, WHO clinical stage, CD4
count, active TB during treatment, and ART regimen had
statistically significant relation with the mortality in adult
HIV-infected patients.
However, in the multivariate analysis, only sex, baseline
performance scale, bodyweight, and WHO clinical stage
were independent significant determinants of mortality.Figure 2 Kaplan-Meier survival curve of 1024 adult HIV-infected patieThe risk of death increased 4.6-fold (95% CI: 2.43- 8.51) in
male compared to female patients. Patients with baseline
performance scale of bedridden <50% were two times
more likely to die compared to patients with normal per-
formance scale at start of treatment (HR 2.05; 95% CI:
1.19- 3.52). However, the risk of mortality increased 3.4
times when the patients had baseline performance scale of
bedridden >50% compared to patients with normal base-
line performance scale (HR 3.41; 95% CI: 1.67- 6.98). For
each kilogram decrease in baseline bodyweight, the risk of
mortality increased by 4% (HR 1.04; 95% CI: 1.01- 1.07).
HIV-infected patients with WHO clinical stage III had
3-fold increased risk of death compared to patients with
stage I or II (HR 2.96; 95% CI: 1.31- 6.69), and the risk
of death among WHO clinical stage IV patients was
even higher- compared to stage I or II patients (HR
3.28; 95% CI: 1.30- 8.29).
In stepwise (backward LR) multivariate analysis, categoriz-
ing baseline CD4 count (into three groups: ≤50 cells/mm3,
51–200 cells/mm3, and >200 cells/mm3) and place of
ART site (into two groups: Hill district (Doti district and
Achham district) and Plain/Terai district (Kailali district
and Kanchanpur district)) showed no statistical signifi-
cant relation with mortality among adult HIV-infected
patients on ART (data not shown).Discussion
This 5-year retrospective cohort study showed high
mortality within 3 months of ART initiation among
HIV-infected patients in Nepal. The major independent
determinants of mortality among adult HIV-infected pa-
tients on ART were male sex, poor baseline perform-
ance scale, low baseline bodyweight, and worse baseline
WHO clinical stage.nts on ART.
Table 1 Mortality rates (per 100 person-years) of HIV-infected
patients over different follow-up time intervals
Follow-up time
intervals
Mortality rate per 100 person-years
at risk (95% CI)
(N = 1024)
0 – 3 months 21.9 (16.6 – 28.8)
0 – 6 months 18.2 (14.6 – 22.6)
0 – 1 year 11.9 (9.7 – 14.5)
0 – 2 years 8.5 (7.1 – 10.3)
0 – 5 years 6.3 (5.3 – 7.6)
Over the study period 6.3 (5.3 – 7.6)
N = total number of patients.
Table 2 Baseline demographic and clinical characteristics






Female 500 (48.8%) 21 (4.2%)
Male 524 (51.2%) 99 (18.9%)
Age (years)
15 – 32 years 338 (33.0%) 27 (8.0%)
33 – 40 years 401 (39.2%) 52 (13.0%)
>40 years 285 (27.8%) 41 (14.4%)
Education
Illiterate 650 (73.5%) 69 (10.6%)
Literate 234 (26.5%) 35 (15.0%)
Missing data 140 (13.6%)
Baseline performance scale
Normal 732 (73.1%) 45 (6.1%)
Bedridden <50% 182 (18.2%) 44 (24.2%)
Bedridden >50% 87 (8.7%) 28 (32.2%)
Missing data 23 (2.2%)
Baseline bodyweight (kg)
< 45 Kg 484 (49.1%) 58 (12.0%)
45 – 60 Kg 479 (48.6%) 49 (10.2%)
>60 Kg 23 (2.3%) 2 (8.7%)
Missing data 38 (3.7%)
Baseline WHO clinical stage
Stage I or II 320 (34.2%) 10 (3.1%)
Stage III 455 (48.6%) 63 (13.8%)
Stage IV 161 (17.2%) 41 (25.5%)
Missing data 88 (8.6%)
Baseline CD4 count (cells/mm3)
≤ 50 cells/mm3 127 (13.6%) 19 (15.0%)
51- 200 cells/mm3 533 (57.1%) 69 (13.0%)
>200 cells/mm3 274 (29.3%) 14 (5.1%)
Missing data 90 (8.8%)
Drug toxicity/side effects
No 788 (80.9%) 83 (10.5%)
Yes 186 (19.1%) 31 (16.7%)
Missing data 50 (4.9%)
Active TB during treatment
No 856 (83.6%) 89 (10.4%)
Yes 168 (16.4%) 31 (18.5%)
Baseline ART regimen#
d4T/3TC/NVP 151 (14.8%) 26 (17.2%)
d4T/3TC/EFV 44 (4.3%) 7 (16.0%)
ZDV/3TC/NVP 702 (69.0%) 64 (9.1%)
ZDV/3TC/EFV 118 (11.6%) 20 (17.0%)
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on ART died, similar with the overall deaths (11.8%) on
ART program in Nepal by July 2011 [13]. The causes of
deaths were not investigated in this study; however, it
is well known that opportunistic infections (OIs) are
the major causes of mortality among HIV-infected
patients. In Nepal, the most prevalent OIs among HIV-
infected patients are tuberculosis, candidiasis and
cryptosporidiosis [17,18].
The overall mortality in this study is quite higher than
in high-income [19], but in line with low-income coun-
tries [6,20]. This could indicate poor ART program initia-
tives and low coverage of the program in Nepal. Similar
to other studies [5,6,21], the first 3 months mortality
after ART initiation was the highest. The poor outcome
in the first few months after ART initiation might be
due to delayed diagnosis and/or treatment and ex-
plained by the fact that 70.7% patients had advanced
disease (CD4 count ≤200 cells/mm3) and 65.7% patients
had advanced clinical symptoms (WHO clinical stage III
or IV) at the time of treatment initiation. Some factors
such as stigma and discrimination related to HIV [10],
limited availability and access to HIV testing and counsel-
ling (HTC) and ART services in most areas might have
played role in delayed diagnosis and/or treatment. More-
over, lack of proper screening of OIs, limited availability of
prophylaxis and diagnostic facility of OIs might also have
increased the mortality [20,22]. Advanced clinical stage
(stage IV) is strongly associated with high mortality dur-
ing the first months of treatment [23].
The variations in the mortality rates across different
countries indicate that effectiveness of ART to reduce
the mortality and increase the survival among HIV-
infected patients could depend on the adherence, quality
of service, and characteristics of patients [4,24].
In Nepal, male HIV-infected patients reported through
HTC by July 2012 were double than female [25]. However,
the proportion of male ART receivers was only 10% more
than female in Nepal [26]. This indicates that female pa-
tients tend to enrol more frequently in ART service than
Table 2 Baseline demographic and clinical characteristics
of 1024 patients on ART (Continued)
TDF/3TC/EFV 3 (0.3%) 0
Missing data 6 (0.6%)
Baseline ART regimen change
No 760 (74.2%) 78 (10.3%)
Yes 264 (25.8%) 42 (16.0%)
ART centre/sub centre
Seti Zonal hospital 590 (57.6%) 51 (8.6%)
Kanchanpur Zonal hospital 70 (6.8%) 13 (18.6%)
Achham District hospital 176 (17.2%) 24 (13.6%)
Doti district hospital 176 (17.2%) 32 (18.2%)
Tikapur hospital 12 (1.2%) 0
acolumn percentage (missing data was excluded);.
brow percentage;.
#all regimen were first line ART regimen.
Note: missing data refers to incomplete/missing recorded characteristics
of patients.
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due to the linkage between the community-based preven-
tion of mother-to-child transmission (CB-PMTCT) and
treatment and care program. Taking PMTCT service
through community level had dramatically increased its
utilization by pregnant mothers and it might have effect-
ively encouraged females to get to know their HIV status
and start early treatment through awareness and counsel-
ling services [27,28].
This study showed that male adult HIV-infected pa-
tients had higher risk of mortality and this is similar to
several [4,5,24], but not all previous studies [20,21], where
the latter showed no significant relationship between sex
and mortality. These differences between several studies
might be due to differences in accessibility and utilization
of health services offered and differences in study setting
explaining cultural differences. Moreover, late reporting to
treatment centre unless experiencing worst HIV related
symptoms might be more prevalent among male patients
[24]. In Mid-and Far-western region of Nepal, the HIV
prevalence is about 5% among male labor migrants [29].
The high prevalence of HIV among male labor migrants,
especially in the Far-western region of Nepal is associated
both with poor knowledge about HIV, stigmatized risk
behaviours delaying health care seeking and poorly devel-
oped health services [29-31]. About 50% - 80% of households
in some communities of Far-western region have at least
one family member working in India, and most of these
migrants (mainly male) especially from Doti, Achham,
Kailali, and Kanchanpur districts seasonally return home
[32]. These migrants are usually the economic pillars of
their families and most of the time of the year they stay
outside of their homes, mainly in India for work [29].
Nevertheless, stigma and discrimination, risky behaviours(alcohol drinking), economic responsibility, guilt about go-
ing to brothels and acquiring HIV-infection when working
abroad, and masculine thought of being strong and
healthy might hinder them to come forward for early test-
ing and treatment.
The association between low baseline bodyweight and
mortality shown in this study is similar to several other
studies, where low bodyweight or body mass index
(BMI) was significantly associated with higher mortality
[4,5,21,24]. Lower bodyweight is a proxy indicator of ad-
vanced disease (low CD4 and worst clinical stage) and
risk factor of opportunistic infections like TB [24,33].
Malnutrition, poor immunity, and poor living standards,
which are associated with low bodyweight, could also be
responsible for the increased risk of mortality.
Adult HIV-infected patients who were bedridden for <50%
or >50% of the days during the past month had higher risk
of mortality compared to the patients with normal base-
line performance status at treatment initiation. A study in
Ethiopia showed similar findings, where bedridden per-
formance status (not able to perform activities of daily
living) was significantly associated with mortality [34]. An-
other study found no significant association, but when lost
to follow-up patients were counted as death cases signifi-
cant association was found [35]. Patients with advanced
clinical diseases (WHO stage III or IV) had higher mortal-
ity compared to patients with WHO stage I or II. This
finding was supported by several other studies done in
Cameroon [4], Zambia [5], Ethiopia [20], Tanzania [24],
and in other low-income countries [36]. The bedridden
performance scale and clinical stage III or IV at ART initi-
ation reflects the worst health condition of patients.
Therefore, the significant effects of these conditions of
patients on mortality indicate that patients died mostly
because of their late initiation of ART when they had
the worst health conditions.
The baseline CD4 count was not significantly associated
with mortality in this study and this finding is consistent
with one previous study [20]. However, most of the previ-
ous studies had contrast findings, where mortality varied
significantly with baseline line CD4 count among HIV-
infected patients. A study in India [6] showed that patients
with CD4 count ≤50 had about three times higher mortal-
ity compared to >50 CD4 count. Another study in
Tanzania [24] found higher mortality among patients with
CD4 count <50 or 50–199 compared to >200 CD4 count.
One more study in low-income countries found that
HIV-infected patients with CD4 count less than 25 died
about three times more than patients with ≥50 CD4
count [36]. In the present study most of the patients
(86.4%) had CD4 count of >50 cells/mm3, which could
have made the comparison with higher CD4 count sta-
tistically unstable. However, examining CD4 count as
continuous variable did not show a significant
Table 3 Hazard ratios (HR) of mortality in 1024 patients on ART
Determinants Univariate analysis Multivariate analysisf
HR (95% CI) P value HR (95% CI) P value
Place of ARTa
Kailali Districb (ref.) 1.00
Kanchanpur Districtb 2.03 (1.10 – 3.73) 0.023
Doti Districtc 1.93 (1.24 – 3.00) 0.004
Achham Districtc 1.71 (1.05 – 2.78) 0.031
Sex
Female (ref.) 1.00 1.00
Male 5.40 (3.37 – 8.65) <0.001 4.55 (2.43 – 8.51) <0.001
Age groups (years)
15- 32 years (ref.) 1.00
33- 40 years 1.66 (1.04 – 2.64) 0.033
>40 years 1.93 (1.19 – 3.14) 0.008
Education
Illiterate (ref.) 1.00
Literate 1.45 (0.96 – 2.17) 0.075
Performance scale
Normal (ref.) 1.00 1.00
Bedridden <50% 4.54 (2.99 – 6.88) <0.001 2.05 (1.19 – 3.52) 0.010
Bedridden >50% 5.53 (3.45 – 8.87) <0.001 3.41 (1.67 – 6.98) 0.001
Bodyweight (Kg)d 1.02(1.01 – 1.05)g 0.048 1.04(1.01 – 1.07)g 0.010
WHO clinical stage
Stage I or II (ref.) 1.00 1.00
Stage III 4.39 (2.25- 8.55) <0.001 2.96 (1.31- 6.69) 0.009
Stage IV 8.85 (4.43-17.66) <0.001 3.28 (1.30- 8.29) 0.012
CD4 count (cells/mm3)d 0.99 (0.98- 0.99) <0.001
Drug toxicity/side effects
No (ref.) 1.00
Yes 1.45 (0.96- 2.19) 0.078
Active TB during treatment
No (ref.) 1.00
Yes 1.73 (1.15- 2.61) 0.009
ART regimene
d4T/3TC/NVP (ref.) 1.00
d4T/3TC/EFV 0.90 (0.39- 2.07) 0.803
ZDV/3TC/NVP 0.49 (0.31- 0.77) 0.002
ZDV/3TC/EFV 0.97 (0.54- 1.73) 0.907
ART regimen change
No (ref.) 1.00
Yes 1.37 (0.94- 2.00) 0.10
aKailali District (Seti Zonal Hospital and Tikapur Hospital), Kanchanpur District (Kanchanpur Zonal Hospital), Doti District (Doti District Hospital), and Achham
District (Achham District Hospital). bplain/terai district, chill district . dContinuous variables. eTDF/3TC/EFV regimen was not included. fCox proportional hazards
model adjusted for all variables in the table. gHR for 1 kg decrease in bodyweight.
ref.: reference group.
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formance scale might have affected the association of
CD4 count with mortality in multivariate analysis. Simi-
larly, the adjustment for sex, and clinical characteristics
(clinical stage, CD4 count, performance scale, and body-
weight) might have affected the independent effects of
other variables (place of ART, age, active TB, ART regi-
men) which had significant effects on mortality in uni-
variate analysis. Nonetheless, the variations in mortality
rates across different ART sites, particularly the lower
rates in Seti Zonal Hospital, could be attributed to the
high rate (22.5%) of transfer-out at this site.
The main strength of this study is that it covers whole
region. This study depicts the ART program outcome of
diverse cultural and ecological regions (hill-difficult top-
ography and plain/terai-easy access to health facility) of
Nepal. This study could be applicable to other region
within or outside Nepal with similar cultural and eco-
logical context. The follow-up time was long enough to
estimate survival and it determinants. This study used
the routine treatment program data, which is cost effect-
ive and the findings would probably give a crucial insight
to develop an effective and efficient HIV treatment, care,
and support program and carved a sustainable way to
respond HIV epidemic in Nepal. A limitation of this
study is the lack of specific information on the causes of
death. Another limitation is the lack of adequate infor-
mation about Cotrimoxazole prophylaxis. Although it is
routinely provided in Nepal, we were unable to include
use of Cotrimoxazole prophylaxis in the analysis due to
its incomplete information in the ART registers. More-
over, the mortality outcome of loss to follow-up patients
in this study was unknown. Lost to follow-up patients
might be at higher risk of death as shown in a meta-
analysis performed in resource-limited settings that on
average 46% of traced loss to follow-up patients on ART
died [37]. However, a worst-case-scenario analysis was
performed, where the mortality rate over the study
period was estimated at 7.1 per 100 person-years at risk
and the same determinants of mortality kept their sig-
nificant association with increased mortality.Conclusions
Over the study period, mortality rate among HIV-infected
patients was high. Majority of deaths were observed within
3 months of ART initiation. Higher mortality among adult
HIV-infected patients was associated with male sex and
poor baseline clinical characteristics i.e. bedridden base-
line performance status, lower baseline bodyweight, ad-
vanced baseline clinical disease (WHO clinical stage III or
IV). Patients (mainly male labour migrants in Far-western
region) should be encouraged to come forward for early
HIV testing and counseling, and to initiate early treatment.HIV-infected patients should to be given proper coun-
seling on nutritional feeding.
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